The role of serological biomarkers in the diagnosis and management of autoimmune pancreatitis

References

• Shimosegawa T, Chari ST, Frulloni L, et al., International consensus diagnostic criteria for autoimmune pancreatitis: guidelines of the international association of pancreatology. Pancreas. 2011;40(3): 352–358.
   PubMed Web of Science ®Google Scholar
• Kamisawa T, Chari ST, Giday SA, et al. Clinical profile of autoimmune pancreatitis and its histological subtypes: an international multicenter survey. Pancreas. 2011;40(6):809–814.
   PubMed Web of Science ®Google Scholar
• Ikeura T, Manfredi R, Zamboni G, et al. Application of international consensus diagnostic criteria to an Italian series of autoimmune pancreatitis. United European Gastroenterol J. 2014;1(4):276–284.
   Web of Science ®Google Scholar
• Stone JH, Zen Y, Despahnde V. IgG4-Related Disease. N Engl J Med. 2012;366(6):539–551.
   PubMed Web of Science ®Google Scholar
• de Pretis N, Frulloni L. Autoimmune pancreatitis type 2. Curr Opin Gastroenterol. 2020;36(5):417–420.
   PubMed Web of Science ®Google Scholar
• Chari ST, Kloeppel G, Zhang L, et al. Histopathologic and clinical subtypes of autoimmune pancreatitis: the Honolulu consensus document. Pancreatology. 2010;10(6):664–672.
   PubMed Web of Science ®Google Scholar
• Desphande V, Zen Y, Chan JK, et al. Consensus statement on the pathology of IgG4-related disease. Mod Patol. 2012;25(9):1181–1192.
   PubMed Web of Science ®Google Scholar
• Zamboni G, Luttges J, Capelli P, et al. Histopathological features of diagnostic and clinical relevance in autoimmune pancreatitis: a study on 53 resection specimens and 9 biopsy specimens. Virchows Arch. 2004;445(6):552–563.
   PubMed Web of Science ®Google Scholar
• Hart PA, Kamisawa T, Brugge WR, et al. Long-term outcomes of autoimmune pancreatitis: a multi center, International analysis. Gut. 2013;62(12):1771–1776.
   PubMed Web of Science ®Google Scholar
• Hart PA, Levy MJ, Smyrk TC, et al. Clinical profiles and outcomes in idiopathic duct-centric chronic pancreatitis (type 2 autoimmune pancreatitis): the Mayo Clinic experience. Gut. 2016;65(10):1702–1709.
   PubMed Web of Science ®Google Scholar
• Zen Y. Type 2 Autoimmune pancreatitis: consensus and controversies. Gut Liver. 2021. DOI:10.5009/gnl210241
   Google Scholar
• Soliman H, Vullierme MP, Maire F, et al. Risk factors and treatment of relapses in autoimmune pancreatitis: rituximab is safe and effective. United European Gastroenterol J. 2019;7(8):1073–1083.
   PubMed Web of Science ®Google Scholar
• Kanno A, Masamune A, Fujishima F, et al. Diagnosis of autoimmune pancreatitis by EUS-guided FNA using a 22-gauge needle: a prospective multicenter study. Gastrointest Endosc. 2016;84(5):797–804.
   PubMed Web of Science ®Google Scholar
• Kurita A, Yasukawa S, Zen Y, et al. Comparison of a 22-gauge Franseen-tip needle with a 20-gauge forward-bevel needle for the diagnosis of type 1 autoimmune pancreatitis: a prospective, randomized, controlled, multicenter study (COMPAS study). Gastrointest Endosc. 2020;91(2):373–381.
   PubMed Web of Science ®Google Scholar
• de Pretis N, Crinò SF, Frulloni L. The role of EUS-guided FNA and FNB in autoimmune pancreatitis. Diagnostics. 2021;11(9):1653.
   Web of Science ®Google Scholar
• Asbun HJ, Conlon K, Fernandez-Cruz L, et al. When to perform a pancreaticoduodenectomy in the absence of positive histology? A consensus statement by the international study group of pancreatic surgery. Surgery. 2014;155(5):887–892.
   PubMed Web of Science ®Google Scholar
• de Pretis N, Amodio A, Frulloni L. Updates in the field of autoimmune pancreatitis: a clinical guide. Expert Rev Gastroenterol Hepatol. 2018;12(7):705.9.
   PubMed Web of Science ®Google Scholar
• Yoshida K, Toki F, Takeuchi T, et al. Chronic pancreatitis caused by an autoimmune abnormality. Proposal of the concept of autoimmune pancreatitis. Dig Dis Sci. 1995;40(7):1561–1568.
   PubMed Web of Science ®Google Scholar
• Hamano H, Kawa S, Horiuchi A, et al. High serum IgG4 concentrations in patients with sclerosing pancreatitis. N Engl J Med. 2001;344(10):732–738.
   PubMed Web of Science ®Google Scholar
• Kamisawa T, Funata N, Hayashi Y, et al., A new clinico-pathological entity of IgG4-related autoimmune disease. J Gastroenterol. 2003;38(10): 982–984.
   PubMed Web of Science ®Google Scholar
• Notohara K, Burgart LJ, Yadav D, et al. Idiopathic chronic pancreatitis with periductal lymphoplasmacytic infiltration: clinicopathologic features of 35 cases. Am J Surg Pathol. 2003;27(8):1119–1127.
   PubMed Web of Science ®Google Scholar
• Hara A, Watanabe T, Minaga K, et al. Biomarkers in autoimmune pancreatitis and immunoglobulin G4-related disease. World J Gastroenterol. 2021;27(19):2257–2269.
   PubMed Web of Science ®Google Scholar
• Khosroshahi A, Carruthers M, Edwards JA, et al. Brief Report: spuriously low serum IgG4 concentrations caused by the prozone phenomenon in patients with IgG4-related disease. Arthritis Rheum. 2013;66(1):213–217.
   Web of Science ®Google Scholar
• Raina A, Krasinskas AM, Greer JB, et al. Serum immunoglobulin G fraction 4 levels in pancreatic cancers: elevations not associated with autoimmune pancreatitis. Acrh Pathol Lab Med. 2008;132(1):48–53.
   PubMed Web of Science ®Google Scholar
• Mahajan VS, Mattoo H, Desphande V, et al. IgG4-related disease. Ann Rev Pathol. 2014;9(1):315–347.
   PubMedGoogle Scholar
• Hao M, Liu M, Fang G, et al. Diagnostic value of serum IgG4 for IgG4-related disease: a PRISMA-compliant systematic review and meta-analysis. Medicine (Baltimore). 2016;95(21):e3785.
   PubMed Web of Science ®Google Scholar
• Lee SC, Yang CH, Chang CT, et al. Diagnostic utility of serum IgG4 in autoimmune pancreatitis. J Clin Gastroenterol. 2021. DOI:10.1097/MCG.0000000000001612.
   Web of Science ®Google Scholar
• Kubota K, Watanabe S, Uchivama T, et al. Factors predictive of relapse and spontaneous remission of autoimmune pancreatitis patients treated/not treated with corticosteroids. J Clin Gastroenterol. 2011;46:834–842.
   Google Scholar
• Shimizu K, Tahara J, Takayama Y, et al. Assessment of the rate of decrease in serum IgG4 level of autoimmune pancreatitis patients in response to initial steroids therapy as a predictor of subsequent relapse. Pancreas. 2016;45(9):1341–1346.
   PubMed Web of Science ®Google Scholar
• Wallace ZS, Khosroshahi A, Carruthers MD, et al., An International multispeciality validation study of the IgG4-related disease responder index. Arthritis Care Res (Hoboken). 2018;70(11): 1671–1678.
   PubMed Web of Science ®Google Scholar
• Rogger TM, De Marchi G, Brozzi L, et al. Immunoglobulin G4-related disease responder index correlates with the risk of 1-year relapse in type 1 autoimmune pancreatitis. Pancreas. 2021;50(6):879–881.
   PubMed Web of Science ®Google Scholar
• Tabibian JH, Lindor KD. Distinguishing immunoglobulin G4-related disease from its pancreatobiliary mimics: are we there now? Hepatology. 2016;64(2):340–343.
   PubMed Web of Science ®Google Scholar
• De Vries E, Tielbeke F, Hubers L, et al. IgG4/IgG RNA ratio does not accurately discriminate IgG4-related disease from pancreatobiliary cancer. JHEP Rep. 2020;14(4):100116.
   Google Scholar
• Miyabe K, Cornell LD, Rajagopalan G, et al. Gastrointestinal and Extra-intestinal manifestations of IgG4-related disease. Gastroenterology. 2018;155(4):990–1003.
   PubMed Web of Science ®Google Scholar
• Shiokawa M, Kodama Y, Kuriyama K, et al. Pathogenicity of IgG in patients with IgG4 related disease. Gut. 2016;65(8):1322–1332.
   PubMed Web of Science ®Google Scholar
• Minaga K, Watanabe T, Hara A, et al. Identification of serum IFN-alfa and IL-33 as novel biomarkers for type 1 autoimmune pancreatitis and IgG4-related disease. Sci Rep. 2020;10(1):14879.
   PubMed Web of Science ®Google Scholar
• Chan ASY, Mudhar H, Shen SY, et al. Serum IgG2 and tissue IgG2 plasma cell elevation in orbital IgG4-related disease (IgG4-RD): potential use in IgG4-RD assessment. Br J Ophtalmol. 2017;101(11):1576–1582.
   PubMed Web of Science ®Google Scholar
• Tang J, Cai S, Ye C, et al. Biomarkers in IgG4-related disease: a systematic review. Semin Arthritis Rheum. 2020;50(2):354–359.
   PubMed Web of Science ®Google Scholar
• Kamisawa T, Chari ST, Lerch MM, et al. Recent advances in autoimmune pancreatitis: type 1 and type 2. Gut. 2013;62(9):1373–1380.
   PubMed Web of Science ®Google Scholar
• Culver EL, Sadler R, Bateman AC, et al. Increases in IgE, eosinophils, and mast cells can be used in diagnosis and to predict relapse of IgG4-related disease. Clin Gastroenterol Hepatol. 2017;15(9):1444–1452.
   PubMed Web of Science ®Google Scholar
• de Buy Wenniger Lj M, Doorenspleet ME, Klarenbeek PL, et al. Immunoglobulin G4+ clones identified by next-generation sequencing dominate the B cell receptor repertoire in immunoglobulin G4 associated cholangitis. Hepatology. 2013;57(6):2390–2398.
   PubMed Web of Science ®Google Scholar
• Doorenspleet ME, Hibers LM, Culver EL, et al. Retracted: immunoglobulin G4 + B-cell receptor clones distinguish immunoglobulin G 4-related disease from primary sclerosing cholangitis and biliary/pancreatic malignancies. Hepatology. 2016;64(2):501–507.
   PubMed Web of Science ®Google Scholar
• Berti A, Della-Torre E, Gallivanon F, et al. Quantitative measurement of 18F-FDG PET/CT uptake reflects the expansion of circulating plasmablasts in IgG4-related disease. Rheumatology (Oxford). 2017;56(12):2084–2092.
   PubMed Web of Science ®Google Scholar
• Mattoo H, Mahajan VS, Della-Torre E, et al. De novo oligoclonal expansions of circulating plasmablasts in active and relapsing IgG4-related disease. J Allergy Clin Immunol. 2014;134(3):678–687.
   Web of Science ®Google Scholar
• Wallace ZS, Mattoo H, Carruthers M, et al. Plasmablasts as biomarker for IgG4-related disease, independent of serum IgG4 concentrations. Ann Rheum Dis. 2015;74(1):190–195.
   PubMed Web of Science ®Google Scholar
• Akiyama M, Yasuoka H, Yoshimoto K, et al. CC-chemokine ligand 18 is a useful biomarker associated with disease activity in IgG4-related disease. Ann Rheum Dis. 2018;77(9):1386–1387.
   PubMed Web of Science ®Google Scholar
• Muraki T, Hamano H, Ochi Y, et al. Autoimmune pancreatitis and complement activation system. Pancreas. 2006;32(1):16–21.
   PubMed Web of Science ®Google Scholar
• Cargill T, Makuch M, Sadler R, et al. Activated T-follicular helper 2 cells are associated with disease activity in IgG4-related sclerosing cholangitis and pancreatitis. Clin Transl Gastroenterol. 2019;10(7):e00069.
   Google Scholar
• Loehr JM, Beuers U, Vujasinovic M, et al. European guideline on IgG4-related digestive disease-UEG and SGF evidence-based recommendations. UEG Journal. 2020;8:637–666.
   Google Scholar
• Scara S, Bottoni P, Scatena R. CA 19-9: biochemical and clinical aspects. Adv Exp Med Biol. 2015;867:247–260.
   PubMed Web of Science ®Google Scholar
• De Marchi G, Paiella S, Luchini C, et al. Very high serum levels of Ca 19-9 in autoimmune pancreatitis: report of four cases and brief review of literature. J Dig Dis. 2016;17:697–702.
   PubMed Web of Science ®Google Scholar
• Chang MC, Liang PC, Jan S, et al. Increase diagnostic accuracy in differentiating focal type autoimmune pancreatitis from pancreatic cancer with combined serum IgG4 and Ca19-9 levels. Pancreatology. 2014;14(5):366–372.
   PubMed Web of Science ®Google Scholar
• Yan T, Ke Y, Chen Y, et al. Serological characteristics of autoimmune pancreatitis and its differential diagnosis from pancreatic cancer by using a combination of carbohydrate antigen 19-9, globulin, eosinophils and hemoglobin. PLoS One. 2017;12:e0174735.
   PubMed Web of Science ®Google Scholar
• Okazaki K, Uchida K, Ohana M, et al., Autoimmune-related pancreatitis is associated with autoantibodies and a Th1/Th2-type cellular immune response. Gastroenterology. 2000;118(3): 573–581.
   PubMed Web of Science ®Google Scholar
• Nishimori I, Miyaji E, Morimoto K, et al. Serum antibodies to carbonic anhydrase IV in patients with autoimmune pancreatitis. Gut. 2005;54(2):274–281.
   PubMed Web of Science ®Google Scholar
• Asada M, Nishio A, Uchida K, et al. Identification of a novel autoantibody against pancreatic secretory trypsin inhibitor in patients with autoimmune pancreatitis. Pancreas. 2006;33(1):20–26.
   PubMed Web of Science ®Google Scholar
• Frulloni L, Lunardi C, Simone R, et al. Identification of a novel antibody associated with autoimmune pancreatitis. N Engl J Med. 2009;361(22):2135–2142.
   PubMed Web of Science ®Google Scholar
• Loehr JM, Faer R, Koczan D, et al. Autoantibodies against the exocrine pancreas in autoimmune pancreatitis: gene and protein expression profiling and immunoassays identify pancreatic enzymes as a major target of the inflammatory process. Am J Gastroenterol. 2010;105(9):2060–2071.
   PubMed Web of Science ®Google Scholar
• Du H, Shi L, Chen P, et al. Prohibitin is involved in patients with IgG4 related disease. PLoS One. 2015;10(5):e0125331.
   PubMed Web of Science ®Google Scholar
• Hubers L, Vos H, Schuurman A, et al. Annexin A11 is targeted by IgG4 and IgG1 autoantibodies in IgG4-related disease. Gut. 2018;67(4):728–735.
   PubMed Web of Science ®Google Scholar
• Zen Y, Grammatikopoulos T, Hadzic N. Autoimmune pancreatitis in children: insights into the diagnostic challenge. J Pediatr Gastroenetrol Nutr. 2014;59(5):42–45.
   Google Scholar